Results 101 to 110 of about 117,898 (292)

ins(9;4)(q33;q12q25) [PDF]

, 2010
Review on ins(9;4)(q33;q12q25), with data on clinics, and the genes ...
Huret, JL
core   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source

S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS

, 2022
A. Laznicka, N. Curik, Václava Polívková, Jitka Koblihova, P. Burda, Alexandra Dolníková, Eva Pokorná, Cyril Šálek, Hana Klamová, Dana Srbová, P. Klener, Kateřina Machová Poláková   +11 more
openalex   +1 more source

Development and targeted use of nilotinib in chronic myeloid leukemia

Drug Design, Development and Therapy, 2008
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour   +3 more
doaj  

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study

European Journal of Haematology, EarlyView.
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham, R. A. Fisher, J. Yang, Y. Guo, U. Bommhardt   +4 more
wiley   +1 more source

From Plastic Waste to Pharmaceutical Precursors: PET Upcycling Through Ruthenium Catalyzed Semi‐Hydrogenation

Angewandte Chemie, Volume 138, Issue 5, 28 January 2026.
We present a new catalytic process that converts real‐life PET waste into ethyl 4‐hydroxymethylbenzoate (EHMB), which serves as a valuable intermediate for the synthesis of pharmaceuticals, an insecticide, and a novel polyester. Abstract We report here the upcycling of PET (polyethylene terephthalate) waste via semihydrogenation to make ethyl 4 ...
Pavel S. Kulyabin, James Luk, Evgeny A. Uslamin, Alexander A. Kolganov, Garima Saini, Raymundo Marcial‐Hernandez, Ketan Pancholi, Benjamin Kühne, Alexander Dauth, Aidan P. McKay, David B. Cordes, Evgeny A. Pidko, Amit Kumar   +12 more
wiley   +2 more sources

β‐elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1

Clinical and Translational Medicine
Background Imatinib has been widely used in gastrointestinal stromal tumours and significantly improved the prognosis of GIST patients, but approximately half of patients develop acquired treatment resistance, highlighting the urgency for novel ...
Jin Lan, Weili Zhang, Kaixuan Zeng, Cong Li, Jiahua He, Xinyue Li, Rong Yang, Jun Chi, Zhigang Hong, Weifeng Wang, Chi Zhou, Binyi Xiao, Wenhua Fan, Junzhong Lin, Qingjian Ou, Yujing Fang, Zhizhong Pan, Jianhong Peng, Weihao Li, Xiaojun Wu   +19 more
doaj   +1 more source

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

Journal of Experimental & Clinical Cancer Research, 2009
Background Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Sparreboom Alex, Figg William D, Smith Nicola F, Gardner Erin R   +3 more
doaj   +1 more source

Comparison of Clinicopathological Parameters, and Treatment Responses in Younger and Older Chronic Myeloid Leukaemia Patients Treated with Imatinib

, 2023
Ahmad Farhan Kamarudin, Sivakumar Palaniappan, Raja Zahratul Azma Raja Sabudin, Salwati Shuib, Siti Afiqah Muhamad Jamil, Nor Rafeah Tumian   +5 more
openalex   +1 more source

CRISPR‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death

The FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9 screen identified H3K27 methylation as a key regulator of T‐cell lymphoma sensitivity to dimethyl fumarate (DMF). Specifically, inhibition of enhancer of zeste homolog 2 (EZH2) enhanced DMF‐induced cell death in malignant T cells. These results provide functional evidence for the role of EZH2 in modulating drug sensitivity and
Jan P. Teubner, Deniz Tümen, Arne Kandulski, Philipp Heumann, Patricia Mester, Elisabeth Aschenbrenner, Kirstin Pollinger, Manuela Gunckel, Barbara Volz, Tobias Hein, Paul L. Beltzig, Luisa Tengler, Florian Voll, Marina Kreutz, Claudia Kunst, Jan P. Nicolay, Martina Müller, Karsten Gülow   +17 more
wiley   +1 more source